Ipsen strengthens its Oncology Presence with a Research Partnership
This year has started on the same basis for Ipsen. In fact, after the acquisition of OctreoPharm Sciences in 2015, a research partnership with start-up PeptiMimesis (France) has been signed to increase its presence in the oncology field.
PeptiMimesis is a start-up from a French National Institute of Health and Medical Research (INSERM) and Strasbourg University spin-off project. It has found a French partner for the development and marketing of novel therapeutic peptides in oncology.
On the other hand, Ipsen, is a French Biotech group which will now combine its expertise in peptide design and development with PeptiMimesis knowledge in the identification of transmembrane peptides and intracellular signalling.
The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation.
PeptiMimesis will receive financial support from Ipsen for the research phases, as well as milestone payments associated to the program. The chairman of PeptiMimesis, Pascal Neuville, explained how this partnership could break the ice into future partnerships with Ipsen.
‘”We are convinced that this initial collaboration will pave the way for a series of partnerships, given the tremendous possibilities of targeting transmembrane receptors”
Ipsen could even make further potential payments to PeptiMimesis at development, regulatory and commercial milestones, as well as royalty payments on worldwide annual net sales.
The field of therapeutic peptides is likely to boost pharmaceutical industry pipelines by providing innovative solutions for unmet medical needs. In fact, peptide-based drug discovery provides a serious option for addressing new therapeutic challenges in multiple pathologies.
Under the terms of the agreement, the closing of this transaction is to move the project forward towards clinical development, and a great step for this French start-up.
Feature Image Credit: Remix of Graphics by Labiotech (Source: INSERM)
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.